Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anghami IncANGH · Entity 7452 | Director | June 29, 2026 | July 14, 2026 |
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Director · Chief Executive Officer | June 03, 2024 | June 05, 2024 |
| Forward Industries, Inc.FORD · Entity 5540 | Director | June 10, 2017 | June 13, 2017 |
| Kenon Holdings Ltd.KEN · Entity 9011 | Director | March 16, 2026 | March 16, 2026 |
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | July 14, 2025 | July 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anghami Inc
Report date June 29, 2026 · Filed July 14, 2026
This filing explicitly reported no securities owned.
Cyclo Therapeutics, Inc.
Report date June 03, 2024 · Filed June 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2034-06-03 | Direct | 266,354 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 266,354 · Balance 266,354 F1: The option vests over a one year period in equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a one year period in equal quarterly installments.
Forward Industries, Inc.
Report date June 10, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,000 |
Reported balance
After 2017-06-10 transaction · row 1
1 source rowRow 1 · 2017-06-10 · Grant · Acquired 35,000 · Balance 105,000 F1: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Not applicable.
Kenon Holdings Ltd.
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,122 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,122 |
Rafael Holdings, Inc.
Report date July 14, 2025 · Filed July 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 335,348 |
Reported balance
Holding disclosure · report date 2025-07-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 335,348 F1: Consists of 331,823 shares of Class B common stock held directly by the Reporting Person and 3,525 shares of Class B common stock held jointly by the Reporting Person and his wife. F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.16 · Expires 2031-08-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.25 · Expires 2032-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.63 · Expires 2033-03-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.63 · Expires 2034-06-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2035-03-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed |
| Class B Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $184.10 · Expires 2025-12-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. F3: These warrants are held jointly by the Reporting Person and his wife. |
| Class B Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.56 · Expires 2027-08-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. F3: These warrants are held jointly by the Reporting Person and his wife. |
| Class B Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2027-10-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-07-14 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025. F3: These warrants are held jointly by the Reporting Person and his wife. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 331,823 shares of Class B common stock held directly by the Reporting Person and 3,525 shares of Class B common stock held jointly by the Reporting Person and his wife.
F2: The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025.
F3: These warrants are held jointly by the Reporting Person and his wife.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2024 Filed Jun 5, 2024 17:08 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to Buy) · Derivative | 266,354 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-24-019343 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,354 Underlying: Common Stock · 266,354 shares Expires 2034-06-03 F1 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 329,342 | Not disclosed Strike: $0.95 | Not disclosed |
DisclosureSEC source: 0001437749-23-028700 · rdgdoc.xml · derivative · entry 3 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,342 Underlying: Common Stock · 329,342 shares Expires 2027-10-20 F1 · price: The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 299,402 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | OtherWarrant to Purchase Common Stock · Derivative | 299,402 | $0.13 Strike: $0.71 | $37,425.25 |
DisclosureSEC source: 0001437749-23-028700 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 299,402 shares Expires 2030-04-20 Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | OtherCommon Stock | 299,402 | $0.71 | $212,575.42 |
DisclosureSEC source: 0001437749-23-028700 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 743,804 F1 · kind: The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 299,402 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:28 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 299,402 | $0.13 Strike: $0.71 | $37,425.25 |
DisclosureSEC source: 0001437749-23-010877 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,402 Underlying: Common Stock · 299,402 shares Expires 2030-04-20 Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:28 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 299,402 | $0.71 | $212,575.42 |
DisclosureSEC source: 0001437749-23-010877 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,402 Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 17:11 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 98,706 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-23-006007 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,706 Underlying: Common Stock · 98,706 shares Expires 2033-03-07 F1 · derivative.exercise_date: The option vests over a four year period in equal monthly installments. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:32 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Options (Right to buy) · Derivative | 74,907 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001437749-22-005023 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,907 Underlying: Common Stock · 74,907 shares Expires 2032-02-28 F1 · derivative.exercise_date: The option vests over a four year period in equal monthly installments. Read SEC document |
| February 07, 2022 Filed Feb 7, 2022 15:50 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 10,334 | $3.58 | $36,995.72 |
DisclosureSEC source: 0001437749-22-002613 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $3.50 to $3.60, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| January 19, 2022 Filed Jan 19, 2022 14:59 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 5,000 | $3.89 | $19,450.00 |
DisclosureSEC source: 0001437749-22-001188 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,666 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $3.87 to $3.89, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 11:19 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 5,000 | $3.89 | $19,450.00 |
DisclosureSEC source: 0001437749-21-028622 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,666 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $3.869 to $3.89, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 16:34 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 5,000 | $4.93 | $24,650.00 |
DisclosureSEC source: 0001437749-21-027709 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,666 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $4.915 to $4.96, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 13:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 5,000 | $5.25 | $26,250.00 |
DisclosureSEC source: 0001437749-21-027140 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,666 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $5.21 to $5.28, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 15:39 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 5,000 | $6.35 | $31,750.00 |
DisclosureSEC source: 0001437749-21-022183 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,666 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $6.29 to $6.38, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 19:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 57,300 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001437749-21-021207 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,300 Underlying: Common Stock · 57,300 shares Expires 2031-08-27 F1 · derivative.exercise_date: The option vests over a four year period in equal monthly installments. Read SEC document |
| January 13, 2021 Filed Jan 25, 2021 20:01 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-001216 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,666 Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-20-025282 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-12-11 F1 · price: The reported securities consist of 20,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-025282 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,666 F1 · price: The reported securities consist of 20,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 16:06 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 500,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001437749-20-018939 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-08-27 F1 · price: The reported securities consist of 500,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 16:06 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-018939 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,966,513 F1 · price: The reported securities consist of 500,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:07 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 730,030 | $0.10 | $73,003.00 |
DisclosureSEC source: 0001437749-20-008579 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,466,513 Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 13:27 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 10,000 | $0.18 | $1,750.00 |
DisclosureSEC source: 0001437749-19-018690 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736,483 Read SEC document |
| July 31, 2019 Filed Jul 31, 2019 11:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 50,000 | $0.25 | $12,500.00 |
DisclosureSEC source: 0001437749-19-015006 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,726,483 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:34 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-011245 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2024-11-30 F1 · price: The reported securities consist of 400,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:34 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-011245 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,676,483 F1 · price: The reported securities consist of 400,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 18:38 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 230,769 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001437749-18-022627 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,769 Underlying: Common Stock · 230,769 shares Expires 2025-12-21 F1 · price: The reported securities consist of 230,769 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 18:38 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 230,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-022627 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,276,483 F1 · price: The reported securities consist of 230,769 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:04 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-012620 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F1 · derivative.expiration_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F3 · ownership.direct: Reflects the conversion of 1,000 shares of Series B Preferred held by the pension plan of a limited liability company of which the reporting person is the sole member, into 400,000 shares of Common Stock. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:04 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionCommon Stock | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-012620 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,045,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. F3 · ownership.direct: Reflects the conversion of 1,000 shares of Series B Preferred held by the pension plan of a limited liability company of which the reporting person is the sole member, into 400,000 shares of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-007687 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2025-04-23 F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseSeries B Convertible Preferred Stock · Derivative | 1,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-007687 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F3 · ownership.direct: Includes 1,000 shares of Series B Preferred held by the pension plan of a limited liability company of which the reporting person is the sole member. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:27 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-001673 · rdgdoc.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,245,714 Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:01 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-17-017327 · rdgdoc.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2024-10-18 F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. F3 · ownership.nature: The Units were purchased by the pension plan of a limited liability company of which the reporting person is the sole member. Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:01 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseSeries B Convertible Preferred Stock · Derivative | 1,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-17-017327 · rdgdoc.xml · derivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F3 · ownership.nature: The Units were purchased by the pension plan of a limited liability company of which the reporting person is the sole member. Read SEC document |
| June 30, 2017 Filed Jul 3, 2017 16:03 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007096 · f4063017fine_ctdholdings.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,225,714 Read SEC document |
| June 10, 2017 Filed Jun 13, 2017 20:00 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003297-17-000184 · fine.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · price: Not applicable. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 16:06 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-003310 · f4033117fine_ctdholdings.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,205,714 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 12:15 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 285,714 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001213900-17-001791 · f4022317fine_ctdholding.xml · derivative · entry 2 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · footnote Disclosed balance after: 285,714 Underlying: Common Stock · 285,714 shares Expires 2024-02-23 F1 · price: The reported securities consist of 285,714 "Units" purchased by the reporting person for $0.35 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. F2 · ownership.nature: The Units were purchased by a limited liability company of which the reporting person is the sole member. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 12:15 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 285,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-001791 · f4022317fine_ctdholding.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,185,714 F1 · price: The reported securities consist of 285,714 "Units" purchased by the reporting person for $0.35 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. F2 · ownership.direct: The Units were purchased by a limited liability company of which the reporting person is the sole member. Read SEC document |
| February 23, 2016 Filed Sep 30, 2016 20:08 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003297-16-000837 · fine.xml · nonDerivative · entry 1 FINE N SCOTT · CIK 0001163556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.